摘要
目的:研究丁苯酞对脑梗死溶栓后患者的疗效及安全性。方法:于我院治疗符合溶栓指征的100例脑梗死患者被随机分为阿替普酶组(48例,接受阿替普酶溶栓治疗)和联合治疗组(52例,在阿替普酶组基础上加用丁苯酞),两组均治疗7d。观察比较两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、发病90d改良Rankin量表(mRS)评分、出血发生率及发病90d死亡率。结果:治疗后,与阿替普酶组比较,联合治疗组NIHSS评分[(14.33±6.15)分比(11.35±6.04)分]、NIHSS维度意识语言[(3.38±2.16)分比(2.15±1.96)分]、运动评分[(7.13±3.08)分比(5.75±2.80)分]均显著降低(P<0.05或<0.01)。两组出血发生率、发病90d内死亡率、发病90d mRS评分比较均无显著差异(P均>0.05)。结论:丁苯酞可显著改善脑梗死溶栓后患者预后,安全性好。
Objective:To study therapeutic effect and safety of butylphthalide in patients with cerebral infarction after thrombolysis.Methods:A total of 100 patients with cerebral infarction meeting indications for thrombolysis who were treated in our hospital were randomly and equally divided into alteplase group(n=48,received alteplase thrombolytic treatment)and combined treatment group(n=52,received butylphthalide based on alteplase group),both groups were treated for 7d.Scores of national institutes of health stroke scale(NIHSS)before and after treatment and modified Rankin scale(mRS)on 90d after onset,incidence rate of bleeding and mortality within 90d after onset were observed and compared between two groups.Results:After treatment,compared with alteplase group,there were significant reductions in scores of NIHSS[(14.33±6.15)scores vs.(11.35±6.04)scores],NIHSS dimension consciousness language[(3.38±2.16)scores vs.(2.15±1.96)scores]and exercise[(7.13±3.08)scores vs.(5.75±2.80)scores]in combined treatment group(P<0.05 or<0.01).There was no significant difference in incidence rate of bleeding,mortality within 90d after onset and mRS score on 90d after onset(P>0.05 all).Conclusion:Butylphthalide can significantly improve prognosis of patients with cerebral infarction after thrombolysis with good safety.
作者
陈捷
程琼
CHEN Jie;CHENG Qiong(Department of Neurology,South Hospital of Fujian Provincial Hospital,Fuzhou,Fujian,350001,China)
出处
《心血管康复医学杂志》
CAS
2021年第6期683-686,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
脑梗死
组织型纤溶酶原激活物
预后
Brain Infarction
Tissue Plasminogen Activator
Prognosis
